Erratum: N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1 (Int J Cancer. (2009) 124, 6 (1322-1329) DOI: 10.1002/ijc.24056);N6-isopentenyladenosine Inhibits cell proliferation and Induces apoptosis In a human colon cancer cell line DLD1

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1322-1329

  Laezza, Chiara ^a   Caruso, Maria Gabriella ^b   Gentile, Teresa ^c   Notarmicola, Maria ^b   Malfitano, Anna Maria ^d   Di Matola, Tiziana ^c   Messa, Caterina ^b   Gazzerro, Patrizia ^d   Bifulco, Maurizio ^d  

^a CNR   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Apoptosis; Colon cancer; JNK; N6 isopentenyladenosine

Indexed keywords

6 N (3,3 DIMETHYLALLYL)ADENOSINE; CASPASE 3; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; LIPOCORTIN 5; P21 WAF PROTEIN; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; MESSENGER RNA; RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL LEVEL; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CELL CYCLE; CELL DIVISION; COLON TUMOR; DNA FRAGMENTATION; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA FRAGMENTATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; ISOPENTENYLADENOSINE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 60549108926     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28917     Document Type: Erratum

References (41)

1. 6-isopentenyladenosine: an emerging anticancer drug. Anticancer Agents Med Chem 2008;8:200-4.
2. Kersten H. On the biological significance of modified nucleosides in tRNA. Prog Nucleic Acid Res Mol Biol 198;431:59-114.
3. Laten HM, Zahareas-Doktor S. Presence and source of free isopentenyladenosine in yeasts. Proc Natl Acad Sci USA 1985;82:1113-5.
4. Laezza C, Migliaro A, Cerbone R, Tedesco I, Santillo M, Garbi C, Bifuico M. N6-isopentenyladenosine affects cAMP-dependent microfilament organization in FRTL-5 thyroid cells. Exp Cell Res 1997;234:178-82.
5. Laezza C, Notarnicola M, Caruso MG, Messa C, Macchia M, Bertini S, Minutolo F, Portella G, Fiorentino L, Stingo S, Bifuico M. N6-iso- pentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB J 2006;20:412-8.
6. Mittelman A, Evans JT, Cheda GB. Cytokinins as chemotherapeutic agents. Ann NY Acad Sci 1975;255:225-34
7. Meisel H, Gunther S, Martin D, Schlimme E. Apoptosis induced by modified ribonucleosides in human cell culture systems. FEBS Lett 1998;433:265-8.
8. Vermeulen K, Strnad M, Havlicek L, Van Onckelen H, Lenjou M, Nijs G, Van Bockstaele DR, Berneman ZN. Plant cytokinin analogues with inhibitory activity on cyclin-dependent kinases exert their antiproliferative effect through induction of apoptosis initiated by the mitochondrial pathway: determination by a multiparametric flow cytometric analysis. Exp Hematol 2002;30:1107-14
9. Ishii Y, Hori Y, Sakai S, Honma Y. Control of differentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant redifferentiation-inducing hormones. Cell Growth Differ 2002;13:19-26
10. Gallo RC, Whang-Peng J. Isopentenyladenosine stimulates and inhibits mitosis of human lymphocytes treated with phytoemoagglutinin. Science 1969;165:400-2
11. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 1996;271:24313-6.
12. Nicoletti I, Migliorati G, Pagliaeci MG, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidiura iodide staining and flow cytometry. J Immunol Meth 1991;139:271-9.
13. Krisans SK, Ericsson J, Edwards PA, Keller GA. Farnesyl-diphos-phate synthase is localized in peroxisomes. J Biol Chem 1994;269:14165-9.
14. Gupta SD, Mehan RS, Tansey TR, Chen HT, Goping G, Goldberg I, Shechter I. Differential binding of proteins to peroxisomes in rat hepatoma cells: unique association of enzymes involved in isoprenoid metabolism. J Lipid Res 1999;40:1572-84.
15. Polyak K, Lee MH, Erdjument-Bromage , Koff A, Roberts JM, Tempst P, Massagué J. Cloning of p27Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
16. Lundberg AS. Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999;35:1886-94.
17. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclis, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
18. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30
19. Harada H, Grant S. Apoptosis regulators. Rev Clin Exp Hematol 2003;7:117-38.
20. Nicholson DW. Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299-306.
21. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371:346-7.
22. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 bv cytotoxic T-cell-derived granzvme B. Nature 1995;377:446-8.
23. Liu X, Kim CN, Yang J, Jeramerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57.
24. Daniel PT. Dissecting the pathways to death. Leukemia 2000;14:2035-44.
25. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999;79:143-80.
26. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-44.
27. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
28. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000;12:1-13.
29. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, et al. SP600125, an anthrapyrazolone Inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98:13681-6.
30. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997;272:12116-21.
31. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000;14:2393-409.
32. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-44.
33. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. Requirement of JNK for stress-Induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-4.
34. Caruso MG, Notarnicola M, Bifuico M, Laezza C, Guerra V, Altomare DF, Memeo V, Lorusso D, Demma I, Di Leo A. Increased Farnesyltransferase activity in human colorectal cancer. Relationship with clinicopathological features, K-ras mutation. Scandinavian J Gastroenterol 2003;38:80-5.
35. Notarnicola M, Messa C, Cavallini A, Bifuico M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG. Higher farnesyl diphosphate synthase activity in human colorectal cancer. Inhibition of cellular apoptosis. Oncology 2004;67:351-8.
36. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40:575-84.
37. McTaggart SJ. Isoprenylated proteins. Cell Mol Life Sci 2006;63:255-67.
38. Wolfman JC, Palmby T, Der CJ, Wolfman A. Cellular N-Ras promotes cell survival bv downregulation of Jun N-terminal protein kinase and p38. Mol Cell Biol 2002;22:1589-606.
39. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006;11:306-15.
40. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007;257:16-35.
41. Cohen LH, Pieterman E, van Leeuwen RE, Du J, Negre-Aminou P, Valentijn AR, Overhand M, van der Marel GA, van Boom JH. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol 2000;60:1061-8.